Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.
[More]
Researchers at the Universitat Politècnica de València and the Universitat de Girona have developed a new method for continuous glucose monitoring in patients with type 1 diabetes.
[More]
Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use.
[More]
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
[More]
The American Association of Clinical Endocrinologists today announced the publication of its comprehensive diabetes management algorithm created to guide primary care physicians, endocrinologists and other health care professionals in the treatment of prediabetes and type 2 diabetes mellitus patients.
[More]
Dr Patrick Tan from A*STAR's Genome Institute of Singapore has received the 2013 Chen New Investigator Award from the international Human Genome Organisation.
[More]
Research from Western University and Lawson Health Research Institute sheds new light on a gene called ATRX and its function in the brain and pituitary.
[More]
Case Western Reserve University's School of Medicine has received a nearly $1 million grant from The Leona M. and Harry B. Helmsley Charitable Trust's Type 1 diabetes program.
[More]
An artificial pancreas system proved more effective at controlling nocturnal glucose levels than a sensor-augmented insulin pump, in a study of children with Type 1 diabetes treated outside the hospital setting in a diabetes camp, report researchers.
[More]
The dual-hormone closed-loop delivery system, a type of artificial pancreas, could offer significant advantages over conventional insulin pump therapy in Type 1 diabetes patients, report researchers.
[More]
Researchers from the Universitat Aut-noma de Barcelona (UAB), led by F-tima Bosch, have shown for the first time that it is possible to cure diabetes in large animals with a single session of gene therapy. As published this week in Diabetes, the principal journal for research on the disease, after a single gene therapy session, the dogs recover their health and no longer show symptoms of the disease.
[More]
Using genome-wide analysis, investigators at the Sainte-Justine University Hospital Research Center and the University of Montreal have potentially eliminated a lifetime drug prescription that two children with a previously unknown type of adrenal insufficiency had been receiving for 14 years.
[More]
IRCM researchers, led by endocrinologist Dr. R-mi Rabasa-Lhoret, were the first to conduct a trial comparing a dual-hormone artificial pancreas with conventional diabetes treatment using an insulin pump and showed improved glucose levels and lower risks of hypoglycemia.
[More]
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
[More]
A new finding in neuroscience for the first time points to a developmental mechanism linking the disease-causing mutation in an autism-related disorder, Timothy syndrome, and observed defects in brain wiring, according to a study led by scientist Ricardo Dolmetsch and published online yesterday in Nature Neuroscience.
[More]
Diabetes is associated with a significantly increased risk for depressive symptoms, show findings from a large meta-analysis.
[More]
University of Texas Medical Branch at Galveston researchers have discovered that the commonly used antidepressant drug paroxetine could also become a therapy for the vascular complications of diabetes.
[More]
Women with bipolar disorder are at increased risk for adverse pregnancy outcomes, results from a Swedish study show.
[More]
Gestational diabetes mellitus (GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during the third trimester of pregnancy). It is defined as carbohydrate intolerance, which is the inability of the body to adequately process carbohydrates (sugars and starches) into energy for the body, that develops or is first recognized during pregnancy.
[More]
A new study in BioMed Central's open access journal Critical Care suggests that intensive glycemic control does not reduce mortality in neurocritical care patients and could, in fact, lead to more neurological damage. Complicating the picture, poor glucose control also leads to worse recovery and should be avoided.
[More]